Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 2/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.33 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 3/20 | 0.32 |
| ▸ | XDH | P47989 | 2/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24849605 | 1.00 | ADORA2B (0.34) | ADORA2BCDK1CCNB1PAK1NR1I2 | |
| SCHEMBL24378687 | 0.85 | — | — | |
| SCHEMBL20621621 | 0.69 | PAK1 (0.38) | ADORA2BCDK1CCNB1PAK1GPR84 | |
| SCHEMBL21643896 | 0.69 | GPR84 (0.37) | PAK1GPR84 | |
| SCHEMBL18948426 | 0.68 | NR1I2 (0.37) | NR1I2GPR84LMNASLC2A1 | |
| SCHEMBL20966632 | 0.68 | HRH3 (0.47) | — | |
| SCHEMBL23791556 | 0.68 | GPR84 (0.39) | ADORA2BNR1I2XDHGPR84 | |
| SCHEMBL19592911 | 0.67 | PAK1 (0.35) | CDK1CCNB1PAK1LMNA | |
| SCHEMBL24489182 | 0.67 | NR1I2 (0.33) | ADORA2BNR1I2GPR84LMNASLC2A1 | |
| SCHEMBL21703615 | 0.67 | CYP1A2 (0.41) | NR1I2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308653-B2 | Diazepane derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20170145023-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308653-B2 | Diazepane derivatives and uses thereof | BRDT, BRD4, BAZ2A | ADORA2B 3648/4885CDK1 404/4885CCNB1 651/4885 |
| US-20170145023-A1 | DIAZEPANE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BAZ2A | ADORA2B 3648/4885CDK1 404/4885CCNB1 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.